The belated US FDA approval of the adenosine A 2A receptor antagonist istradefylline for treatment of Parkinson’s disease

Purinergic signalling

article

Jiang-Fan Chen¹  Rodrigo A. Cunha² 

[1] Molecular Neuropharmacology Laboratory, Wenzhou Medical University;CNC-Center for Neuroscience and Cell Biology, Faculty of Medicine, University of Coimbra

关键词: Adenosine;    A2A receptor;    Parkinson_s disease;    istradefylline;    KW6002;    clinical trial .safety;    Therapy;   

DOI  :  10.1007/s11302-020-09694-2

学科分类：分子生物学，细胞生物学和基因

来源: Springer

【 摘 要 】

After more than two decades of preclinical and clinical studies, on August 27, 2019, the US Food and Drug Administration (FDA) approved the adenosine A2A receptor antagonist Nourianz® (istradefylline) developed by Kyowa Hakko Kirin Inc., Japan, as an add-on treatment to levodopa in Parkinson’s disease (PD) with “OFF” episodes. This milestone achievement is the culmination of the decade-long clinical studies of the effects of istradefylline in more than 4000 PD patients. Istradefylline is the first non-dopaminergic drug approved by FDA for PD in the last two decades. This approval also provides some important lessons to be remembered, namely, concerning disease-specific adenosine signaling and targeting subpopulation of PD patients. Importantly, this approval paves the way to foster entirely novel therapeutic opportunities for adenosine A2A receptor antagonists, such as neuroprotection or reversal of mood and cognitive deficits in PD and other neuropsychiatric diseases.

【 授权许可】

CC BY